Clinical trial NCT02302092: An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
Official title: A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Urinary Tract Infection
Keywords: Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2014-11-26
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the effectiveness of antibiotic flomoxef with cefepime for the treatment of complicated urinary tract infections (cUTIs) in Russian adults.

Detailed description: The drug being tested in this study is called Flomoxef. Flomoxef is being tested in people with a complicated urinary tract infection (cUTI) including a kidney infection. This study compares Flomoxef to Cefepime, another antibiotic.

The study enrolled 13 patients.

Participants are randomly assigned by a computer generated number to one of two treatment groups:

* Flomoxef - intravenous infusion 2g twice daily (every 12 hours); or
* Cefepime - intravenous infusion 1g twice daily (every 12 hours).

This multi-center trial is conducted at 4 sites in the Russian Federation. The overall time to participate in this study is 30+/-3 days. Participants make six visits to the clinic.

Study was prematurely terminated due to administrative and strategic reasons.

Eligibility criteria: Inclusion Criteria:

1. Is a man or woman aged 18 to 70 years, inclusive.
2. Has pyuria (a white blood cell \[WBC\] count greater than 10/μL in unspun urine or greater than or equal to 10 per high power field in spun urine).
3. Has clinical signs and/or symptoms of a complicated lower urinary tract infection (UTI) and/or acute pyelonephritis that include one or more of the following: fever (i.e, axillary temperature greater than 37.7°C), chills, malaise, flank pain, back pain, and/or costo-vertebral angle pain or tenderness and/or any symptoms of dysuria (dysuria, urinary urgency, urinary frequency, suprapubic discomfort, new urinary incontinence or worsening of pre-existing incontinence) that occur in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of catheterization.
4. Has a pretreatment baseline urine culture specimen obtained within 24 hours before the administration of the first dose of study drug (NOTE: Participants may be enrolled in this study and start intravenous (IV) study drug therapy before the Investigator knows the results of the baseline urine culture).
5. Requires IV antibacterial therapy for the treatment of the presumed complicated UTI (cUTI).
6. In the opinion of the investigator, is capable of understanding and complying with protocol requirements.
7. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures, or has a legally acceptable representative sign the forms.
8. Meets protocol-specified criteria regarding the use of contraception; and 9-Is willing and able to comply with study procedures.

Exclusion Criteria:

1. Has received any investigational compound within 30 days of screening.
2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, or sibling) or may consent under duress.
3. Is a female participant who is pregnant or lactating or intending to become pregnant before, during, or within one month after participating in this study, or intends to donate ova during such time period.
4. Is a male participant who intends to donate sperm during the course of this study or for 12 weeks thereafter.
5. Has participated in another clinical study within the past 30 days.
6. Has a history of allergy to or intolerance of beta-lactams (penicillins, cephalosporins or carbopenems).
7. Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff, 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding), or 3) the analysis of results.
8. Has received any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before administration of the first dose of study drug.
9. Has received any dose of a potentially therapeutic antibacterial agent for the treatment of the current UTI within 48 hours before providing the pretreatment baseline urine culture specimen.
10. Has a current urinary catheter that is not scheduled to be removed before the End-of-Therapy (EOT) visit (intermittent straight catheterization during the IV study drug administration period is acceptable).
11. Has any history of trauma to the pelvis or urinary tract within one year before the screening visit.
12. Has any other contraindications to the medicines that are to be used in the study (according to the manufacturer's instructions).
13. Is considered unlikely to survive the four-week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).

Primary outcomes:
measure: Percentage of Participants Who Achieved Resolution of All Clinical Symptoms of a Complicated Urinary Tract Infection (cUTI) at the End of Treatment (EOT) Visit
timeFrame: Baseline and Days 7 to 14
Secondary outcomes:
measure: Percentage of Participants With Microbiological Success at the EOT and Test-of-Cure (TOC) Visits
timeFrame: Baseline, Days 7 to 14 and 14 to 21
measure: Percentage of Participants Who Achieved Clinical Resolution of Symptoms of a cUTI at Visit 3, TOC and Late Follow-up (LFU) Visits
timeFrame: Baseline, Days 3, 14 to 21 and 30
measure: Percentage of Participants With Microbiologic Eradication of the Unique Pathogen at the EOT and TOC Visits
timeFrame: Baseline, Days 7 to 14 and 14 to 21
measure: Percentage of Participants With Microbiologic Persistence of the Unique Pathogen at the EOT and TOC Visits
timeFrame: Baseline, Days 7 to 14 and 14 to 21
measure: Percentage of Participants With a New Infection at the EOT and TOC Visits
timeFrame: Baseline, Days 7 to 14 and 14 to 21
measure: Percentage of Participants With a Superinfection at the EOT and TOC Visits
timeFrame: Baseline, Day 7 to 14 and 14 to 21
measure: Number of Participants With Serious Adverse Events (SAEs) and Treatment-Emergent-Adverse Events (TEAEs)
timeFrame: Baseline up to Day 30
measure: Number of Participants With Clinically Significant Abnormal Laboratory Values
timeFrame: Day 21
measure: Number of Participants With Clinically Significant Change in Vital Signs
timeFrame: Day 1 up to Day 21
measure: Number of Participants With Clinically Significant Change in Physical Examination Findings
timeFrame: Day 1 up to Day 21
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
city: Rostov-on-Don
country: Russian Federation
city: Saint Petersburg
country: Russian Federation
city: Volgograd
country: Russian Federation
city: Yaroslavl
country: Russian Federation
Study officials:
affiliation: Takeda
name: Medical Director Clinical Science
role: STUDY_DIRECTOR
References: